Equity | Note 16 – Equity Common Stock The following is a summary of common stock issuances for the nine months ended March 31, 2022: ● During the nine months ended March 31, 2022, as part of the March 2022 Offering, the Company sold 15,000,000 units at $ 1.00 , consisting of one share of common stock and one warrant with an exercise price of $ 1.00 , for gross proceeds of $ 15,000,000 . The Company recorded the issuance of these shares at a fair value of $ 4,051,500 comprised of $ 13,605,000 of cash received from the offering equal to the gross proceeds net of $ 1,395,000 issuance costs, and net of the fair value of the warrant liability calculated on issuance of $ 9,553,500 . The proceeds from the offering were designated for general working capital and to pay to the Holder of the Senior Convertible Note an amount equal to 30% of the gross proceeds to applied as a reduction of principal (see Note 12). At March 31, 2022 the Company has not remitted payment to the Holder and principal remains at $ 35,000,000 . ● During the nine months ended March 31, 2022, the Company issued 132,527 4.70 ● During the nine months ended March 31, 2022, the Company issued 14,000 shares of common stock from the exercise of stock options with a weighted average exercise price of $ 4.82 per share or $ 67,479 in the aggregate. ● During the nine months ended March 31, 2022, the Company issued 1,165,813 4,005,267 3,885,109 3.44 ● During the nine months ended March 31, 2022, the holder of the Senior Convertible Note converted an aggregate conversion value of $ 10,652,648 2,514,459 4.24 The following is a summary of common stock issuances for the nine months ended March 31, 2021: ● On February 11, 2021, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors resulting in the raise of $ 30,000,000 2,000,000 0.001 15.00 27,340,000 ● During the nine months ended March 31, 2021, the Company issued 650,000 3,802,500 ● During the nine months ended March 31, 2021, the Company issued a total of 187,616 2,217,621 93,808 411,817 93,808 1,805,804 ● During the nine months ended March 31, 2021, the Company issued 292,511 2,193,833 ● During the nine months ended March 31, 2021, the Company issued 4,274,393 5.85 24,986,582 ● During the nine months ended March 31, 2021, the Company issued 1,000,000 8.00 15,480,000 8,000,000 7,480,000 2,750,076 4,729,924 ● During the nine months ended March 31, 2021, the Company issued 528,997 6.22 3,290,570 At-the Market Equity Offering Program On September 3, 2021, the Company entered “at the market” equity offering program to sell up to an aggregate of $ 20,000,000 of common stock. The shares are being issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-252370) and the Company filed a prospectus supplement, dated September 3, 2021 with the SEC in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement with the broker. There were 1,165,813 shares sold under the ATM during the nine months ended March 31, 2022 for gross proceeds of $ 4,005,267 . The Company had $ 15,994,733 of gross proceeds remaining under the ATM at May 20, 2022. Common Stock Warrants On March 2, 2022, the Company closed an offering March 2022 Offering, in which it sold 15,000,000 1.00 15,000,000 1.00 On July 31, 2020, the Company issued 1,000,000 8.00 2,000,000 2,000,000 17.50 On April 16, 2020, the Company closed an offering, (the “April 2020 Offering”), in which it sold 1,980,000 3,960,000 4.25 209,400 209,400 0.01 1,136,763 no In connection with the April 2020 Offering the Company also issued 1,217,241 2,434,482 4.25 4,138,585 40,582 A summary of the warrant activity follows: Schedule of Warrant Activity Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life (Years) Intrinsic Value Outstanding, July 1, 2020 5,264,592 $ 4.28 0.86 $ 14,654,296 Issued 5,603,674 14.38 Exercised ( 5,503,167 ) 4.88 Exchanged — — Forfeited or cancelled ( 14,541 ) 4.25 Outstanding, June 30, 2021 5,350,558 14.19 3.14 8,743,588 Issued — — Exercised — — Forfeited or cancelled — — Outstanding, September 30, 2021 5,350,558 14.19 2.89 3,138,768 Issued — — Exercised — — Forfeited or cancelled — — Outstanding, December 31, 2021 5,350,558 14.19 2.64 — Issued 15,000,000 1.00 Exercised — — Forfeited or cancelled — — Outstanding, March 31, 2022 20,350,558 $ 4.47 4.26 $ — Common Stock Options On September 10, 2020, the Company’s Board of Directors adopted the 2020 Equity and Incentive Plan (the “2020 Plan”) that provides for the issuance of incentive and non-qualified stock options, restricted stock, restricted stock units and stock appreciation rights to officers, employees, directors, consultants, and other key persons. Under the 2020 Plan, the maximum number of shares of common stock authorized for issuance was 1,500,000 shares. Each year on January 1, for a period of up to nine years, the maximum number of shares authorized for issuance under the 2020 Plan is automatically increased by 233,968 shares . At March 31, 2022, there was a maximum of 1,967,936 shares of common stock authorized for issuance under the 2020 Plan. There were no additional equity awards eligible for issuance from the 2017 Stock Incentive Plan that had been adopted by the Company on August 1, 2017. The outstanding stock options granted under the 2017 Plan were transferred to the 2020 Plan. As of March 31, 2022, there were 608,535 shares of common stock available for future issuance under the 2020 Plan. A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Outstanding, June 30, 2021 474,676 $ 5.49 Granted — — Exercised (8,500 ) — Cancelled — — Outstanding, September 30, 2021 466,176 5.41 Granted 1,120,150 6.71 Exercised (5,500 ) 4.82 Cancelled (50,675 ) 9.11 Outstanding, December 31, 2021 1,530,151 6.27 Granted — — Exercised — — Cancelled (170,750 ) 6.19 Outstanding, March 31, 2022 1,359,401 $ 6.28 As of March 31, 2022, the weighted average remaining life of the options outstanding was 4.34 860,451 6.03 Stock Based Compensation During the three months ended March 31, 2022 and 2021, the Company recorded stock-based compensation expense of $ 1,346,502 743,527 3,958,275 3,055,118 The Company had previously recognized stock-based compensation expense of $ 927,855 117,450 1,333 16,966 99,151 As of March 31, 2022, unamortized stock compensation for stock options was $ 2,636,626 0.50 Schedule of Weighted Average Assumptions Valued Using Black-Scholes Option Pricing Model Nine months ended March 31, 2022 Expected term, in years 2.81 Expected volatility 150.82 % Risk-free interest rate 0.45 % Dividend yield — Grant date fair value $ 5.33 |